Harvard Bioscience, Inc. will present its latest product innovations at the Society of Toxicology (SOT) conference, further advancing preclinical research and organoid-based therapeutic development. Key highlights include the expansion of the SoHo™ Implantable Real-Time Telemetry Platform, the VivaMARS™ Activity Monitoring System, and the Mesh MEA™ Organoid Platform. These cutting-edge solutions promise to enhance research capabilities while reducing costs and cycle times in drug development.

Key Innovations on Display:

• SoHo™ Implantable Telemetry Platform:
  Harvard Bioscience will introduce its new SoHo biopotential monitoring devices, aimed at improving neurotoxicity and cardiovascular toxicology studies. These devices integrate with the Ponemah data management platform, streamlining data collection and analysis.

• VivaMARS™ Activity Monitoring System:
  A GLP-compliant platform for real-time behavioral analysis, designed to meet the needs of CROs and pharmaceutical companies. Harvard Bioscience will present a poster in collaboration with a leading CRO, showcasing the first adoption of the VivaMARS technology.

• Mesh MEA™ Organoid Platform:
  The company will highlight its advanced Mesh Microelectrode Array (MEA) system for organoid applications, enabling precise electrophysiological readings from living organoids, supporting research, safety pharmacology, and toxicology studies.

Harvard Bioscience continues to drive innovation, aiming to accelerate the development of new therapies while reducing time to market and increasing testing throughput.